

Optimax Holdings Berhad (“**Optimax**” or the “**Company**”) had, at its Second (2nd) Annual General Meeting held on 29 June 2021 obtained the mandate from its shareholders to enter into recurrent related party transactions of revenue or trading nature (“**RRPT**”) which are necessary for Optimax and its subsidiaries’ (“**Optimax Group**”) day-to-day operations.

Pursuant to Rule 10.09(2)(e) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of Optimax, wishes to announce that the actual value of the RRPT below had exceeded the estimated value of the RRPT disclosed in the circular to shareholders dated 1 June 2021 (“**Circular**”) by more than 10%.

Further details are as follows:

Related Party	Interested Director	Nature of transaction	Estimated value disclosed in the Circular (RM'000)	Actual value transacted from 29 June 2021 to 31 March 2022 (RM'000)	Amount exceeded (RM'000)	Reason for the variation
OESC and Aquiline Eyecare Training Enterprise	Interested director <ul style="list-style-type: none"> • Dr. Yen Siew Siang 	Payment of fees by OESC to Aquiline Eyecare Training Enterprise for the provision of professional services provided by Dr. Yen Siew Siang	300	355	55	Note (a)

Note:

(a) The actual value transacted deviated by more than 10% from the estimated value disclosed in the Circular is due to higher sales recorded by Aquiline Eyecare Training Enterprise as a result of the professional services provided by Dr Yen Siew Siang.

The announcement is dated 20 April 2022.